English
Cohance Lifesciences Q4 Results
- BSE: 543064
- NSE: COHANCE
- ISIN: INE03QK01018
- Sector: Biotechnology & Drugs
BSE
528.25
-7.00 (-1.31%)
-7.00 (-1.31%)Volume19.39 K
Updated: Wed 10 Dec, 2025 | 15:50:11
NSE
528.45-6.55 (-1.22%)
-6.55 (-1.22%)Volume3.90 L
Updated: Wed 10 Dec, 2025 | 15:55:23
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Cohance Lifesciences Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 24 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 355.24 | 209.80 | 69.32% | 194.46 | 82.68% |
| Depreciation/ Amortization | 26.78 | 20.35 | 31.60% | 17.41 | 53.81% |
| Operating Income | 46.78 | 97.35 | -51.95% | 58.47 | -19.99% |
| Net Income | 42.01 | 82.88 | -49.31% | 53.37 | -21.29% |
| Other Operating Expenses Total | 105.38 | 70.53 | 49.41% | 5.12 | 1957.16% |
| Net Income Before Taxes | 51.60 | 109.73 | -52.98% | 70.85 | -27.17% |
| Total Revenue | 402.02 | 307.15 | 30.89% | 252.93 | 58.94% |
| Selling/ General/ Admin Expenses Total | 89.08 | 63.29 | 40.75% | 45.77 | 94.64% |
| Diluted Normalized EPS | 1.64 | 3.23 | -49.18% | 2.20 | -25.23% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.